1501O Long-term estimates of cancer incidence and mortality for the EU and EFTA countries according to different demographic scenarios

Abstract

Background: Long-term projections of cancer burden are an important input to health-policy planning. Major cancer risk factors e such as genetics, lifestyle, environmental exposure to carcinogens, in combination with the associated population structures e impact on observed number of cancer incidence and mortality cases. The latest estimates on cancer burden in the EU and EFTA countries for the year 2020 predicted 2.8 million new cancer cases and 1.3 million cancer deaths. This study investigates how these numbers would change up to the year 2040 under different population structures, assuming the estimated 2020 cancer incidence and mortality crude rates remain the same.Methods: Using the estimated 2020 cancer incidence and mortality crude rates and the projected populations for years 2025, 2030, 2035 and 2040, as released by Eurostat, cancer incidence and mortality was projected by age, sex, country, and cancer site. Alternative projections were computed using different population structures, also released by Eurostat, modelled on the following demographic scenarios: 20% lower fertility rate, lower mortality rate, 33% lower migration rate, nomigration and 33% higher migration rate as compared to the 2020 baseline. Results:The number of new cancer cases in the EU and EFTA countries is estimated to increase to 3.4 million by 2040, with an increment of 21.4%. The increment is estimated to be highest in the scenario with lower mortality (23.3%), while it is lowest for the no-migration scenario (19.7%). Large variability is estimated among the different cancer sites, varying from a decrease of 5.2% for testicular cancer up to an increase of 35.2% for the mesothelioma in males. The variability is highest for the no-migration and lower mortality scenarios. The number of cancer deaths in the EU and EFTA countries is estimated to grow to 1.7 million by 2040, with an increment of 32.2%, increasing up to 35.4% for the lower mortality scenario. Conclusions:The results obtained are of big value in planning health policies for cancer in the EU and EFTA region.Legal entity responsible for the study: The authors.

Phytochemical Composition, Antioxidant, and Anticancer Activities of Sidr Honey: In Vitro and In Silico Computational Investigation

“…Breast, lung, and colorectal cancer are the main types of cancer detected in both males and females, with respective rates of 11.7%, 11.4%, and 10% [ 1 ]. The number of new diagnostic cases of cancer may rise to 32.2 million in 2040 [ 2 ].…”

Perceived Dignity of Advanced Cancer Patients and Its Relationship to Sociodemographic, Clinical, and Psychological Factors

“…Cancer is one of the leading causes of death worldwide; its incidence has increased progressively in recent years, and the number of cases is expected to increase by 2040 ( Dyba et al, 2021 ). Many patients perceive receiving a diagnosis of cancer and the subsequent treatment procedures as stressful, putting individuals with advanced cancer at high risk of suffering psychological problems ( Hinz et al, 2010 ; Zhu et al, 2017 ; Pitman et al, 2018 ).…”

The protein phosphatase-2A subunit PR130 is linked to cytotoxic protein aggregate formation in mesenchymal pancreatic ductal adenocarcinoma cells

“…Annual new cancer cases will increase by 21.4% in Europe in the next decade. 1 Within the malignant neoplasms, pancreatic ductal adenocarcinoma (PDAC) remains a particularly dismal disease. The incidence and mortality of PDAC are increasing and the disease is expected to become the second leading cause of cancer-related deaths, with a current 5-year survival rate of only 12%.…”